PFIZER INC
PFEAPI behind this page
PFE Q3 2025 request
Playground key active
/api/financials?ticker=PFE&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 13,920 | 15,417 | -9.7% |
| Royalty | 436 | 384 | +13.5% |
| Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer | 2,298 | 1,900 | +20.9% |
Show Product Lines breakouts |
|||
| Total Alliance revenues [Member] | 2,298 | 1,900 | +20.9% |
| Revenue | 16,654 | 17,702 | -5.9% |
Show Product Lines breakouts |
|||
| Abrysvo [Member] · Biopharma [Member] | 279 | 356 | -21.6% |
| Adcetris [Member] · Biopharma [Member] | 215 | 268 | -19.8% |
| All other Hospital [Member] · Biopharma [Member] | 985 | 1,041 | -5.4% |
| All other Oncology [Member] · Biopharma [Member] | 272 | 268 | +1.5% |
| All other Primary Care [Member] · Biopharma [Member] | 721 | 742 | -2.8% |
| All other Specialty Care [Member] · Biopharma [Member] | 407 | 323 | +26.0% |
| Aromasin [Member] · Biopharma [Member] | 114 | 87 | +31.0% |
| Bosulif [Member] · Biopharma [Member] | 150 | 161 | -6.8% |
| Braftovi/Mektovi [Member] · Biopharma [Member] | 202 | 173 | +16.8% |
| Cibinqo [Member] · Biopharma [Member] | 79 | 63 | +25.4% |
| Comirnaty [Member] · Biopharma [Member] | 1,151 | 1,422 | -19.1% |
| Cresemba [Member] · Biopharma [Member] | 83 | 67 | +23.9% |
| Eliquis [Member] · Biopharma [Member] | 2,015 | 1,617 | +24.6% |
| Elrexfio [Member] · Biopharma [Member] | 85 | 40 | +112.5% |
| Enbrel (Outside the U.S. and Canada) [Member] · Biopharma [Member] | 154 | 169 | -8.9% |
| FSME-IMMUN/TicoVac [Member] · Biopharma [Member] | 100 | 81 | +23.5% |
| Genotropin [Member] · Biopharma [Member] | 128 | 119 | +7.6% |
| Ibrance [Member] · Biopharma [Member] | 1,057 | 1,087 | -2.8% |
| Inflectra [Member] · Biopharma [Member] | 173 | 126 | +37.3% |
| Inlyta [Member] · Biopharma [Member] | 226 | 247 | -8.5% |
| Lorbrena [Member] · Biopharma [Member] | 268 | 206 | +30.1% |
| Nurtec ODT/Vydura [Member] · Biopharma [Member] | 412 | 337 | +22.3% |
| Octagam [Member] · Biopharma [Member] | 113 | 221 | -48.9% |
| Oncology Biosimilars [Member] · Biopharma [Member] | 315 | 285 | +10.5% |
| Orgovyx [Member] · Biopharma [Member] | 112 | 57 | +96.5% |
| Padcev [Member] · Biopharma [Member] | 464 | 409 | +13.4% |
| Paxlovid [Member] · Biopharma [Member] | 1,225 | 2,703 | -54.7% |
| Pfizer CentreOne [Member] | 344 | 285 | +20.7% |
| Prevnar Family [Member] · Biopharma [Member] | 1,742 | 1,803 | -3.4% |
| Sulperazon (Outside the U.S. and Canada) [Member] · Biopharma [Member] | 154 | 156 | -1.3% |
| Talzenna [Member] · Biopharma [Member] | 47 | 36 | +30.6% |
| Tivdak [Member] · Biopharma [Member] | 37 | 34 | +8.8% |
| Tukysa [Member] · Biopharma [Member] | 110 | 124 | -11.3% |
| Vyndaqel family [Member] · Biopharma [Member] | 1,591 | 1,447 | +10.0% |
| Xeljanz [Member] · Biopharma [Member] | 313 | 321 | -2.5% |
| Xtandi [Member] · Biopharma [Member] | 578 | 561 | +3.0% |
| Zavicefta (Outside the U.S. and Canada) [Member] · Biopharma [Member] | 158 | 152 | +3.9% |
| Zithromax [Member] · Biopharma [Member] | 73 | 83 | -12.0% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 16,310 | 17,392 | -6.2% |
| Biopharma [Member] · International Commercial Division [Member] | 5,711 | 5,428 | +5.2% |
| Biopharma [Member] · Oncology [Member] | 4,253 | 4,043 | +5.2% |
| Biopharma [Member] · Operating Segments | 16,310 | 17,392 | -6.2% |
| Biopharma [Member] · Primary Care [Member] | 7,646 | 9,060 | -15.6% |
| Biopharma [Member] · Specialty Care [Member] | 4,411 | 4,289 | +2.8% |
| Biopharma [Member] · U.S. Commercial Division [Member] | 10,599 | 11,964 | -11.4% |
Show Geography breakouts |
|||
| International Developed Markets [Member] | 3,696 | 3,412 | +8.3% |
| International Emerging Markets [Member] | 2,267 | 2,226 | +1.8% |
| US | 10,691 | 12,064 | -11.4% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 344 | 310 | +11.0% |
| Cost of Revenue | 4,172 | 5,263 | -20.7% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 3,526 | 4,630 | -23.8% |
| Selling, General & Administrative | 3,186 | 3,244 | -1.8% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 2,210 | 2,253 | -1.9% |
| Research And Development Expense Excluding Acquired In Process Cost | 2,546 | 2,598 | -2.0% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 2,185 | 2,355 | -7.2% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 1,390 | 13 | +10592.3% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 40 | 13 | +207.7% |
Show Counterparty Name breakouts |
|||
| 3SBio [Member] · In-Licensing Agreement Option [Member] | 1.35 | — | — |
| Amortization Of Intangible Assets Not Associated With Single Function | 1,223 | 1,312 | -6.8% |
| Restructuring Charges And Acquisition Related Costs | 286 | 313 | -8.6% |
| Other Non-Operating Income (Expense) | 517 | 243 | +112.8% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | -120 | -128 | +6.2% |
| Income Before Taxes | 3,334 | 4,715 | -29.3% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 8,469 | 8,269 | +2.4% |
| Biopharma [Member] · Operating Segments | 8,469 | 8,269 | +2.4% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -3,084 | -1,477 | -108.8% |
| Material Reconciling Items · Acquisition-Related Items [Member] | -194 | -465 | +58.3% |
| Material Reconciling Items · Amortization of Intangible Assets [Member] | -1,223 | -1,312 | +6.8% |
| Material Reconciling Items · Certain Significant Items [Member] | -634 | -299 | -112.0% |
| Income Tax Expense (Benefit) | -216 | 234 | -192.3% |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | 3,550 | 4,481 | -20.8% |
| Net Income | 3,550 | 4,473 | -20.6% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 9 | 8 | +12.5% |
| Parent | 3,541 | 4,465 | -20.7% |
| Retained Earnings | 3,541 | 4,465 | -20.7% |
| Net Income Loss Attributable To Noncontrolling Interest | 9 | 8 | +12.5% |
| Net Income | 3,541 | 4,465 | -20.7% |
| Income Loss From Continuing Operations Per Basic Share | 0.62 | 0.79 | -21.5% |
| EPS (Basic) | 0.62 | 0.79 | -21.5% |
| Income Loss From Continuing Operations Per Diluted Share | 0.62 | 0.79 | -21.5% |
| EPS (Diluted) | 0.62 | 0.78 | -20.5% |
| Wtd Avg Shares (Basic) | 5,685 | 5,667 | +0.3% |
| Wtd Avg Shares (Diluted) | 5,714 | 5,705 | +0.2% |
| Interest Income | -138 | -116 | -19.0% |
| Comprehensive Income | 3,913 | 4,310 | -9.2% |
| Net Income Loss Available To Common Stockholders Basic | 3,541 | 4,465 | -20.7% |
| Interest Expense | 652 | 783 | -16.7% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,343 | 1,092 | +23.0% |
| Accounts Receivable | 14,260 | 14,451 | -1.3% |
| Inventory | 11,468 | 11,721 | -2.2% |
| Other Tax Assets Current | 3,855 | 3,243 | +18.9% |
| Other Assets Current | 2,358 | — | — |
| Total Current Assets | 46,924 | 43,223 | +8.6% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 18,880 | 18,541 | +1.8% |
| Goodwill | 69,101 | — | — |
| Deferred Tax Assets Net And Other Tax Assets Noncurrent | 11,048 | 7,909 | +39.7% |
| Other Non-Current Assets | 9,317 | 10,486 | -11.1% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · Fair Value Measurements Recurring | 1,093 | 1,231 | -11.2% |
Show Fair Value By Measurement Frequency breakouts |
|||
| Fair Value Measurements Recurring | 1,093 | 1,231 | -11.2% |
| Total Assets | 208,731 | 219,476 | -4.9% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level1 · Fair Value Measurements Recurring | 1,176 | 1,368 | -14.0% |
| Fair Value Inputs Level2 · Fair Value Measurements Recurring | 13,909 | 9,787 | +42.1% |
Show Fair Value By Measurement Frequency breakouts |
|||
| Fair Value Measurements Recurring | 15,085 | 11,154 | +35.2% |
| Intangible Assets | 33,513 | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Developed Technology Rights | 32,163 | — | — |
| License Agreements and Other [Member] | 1,099 | — | — |
| Trade Names | 251 | — | — |
| Other Assets | |||
| Other Short Term Investments | 13,641 | 8,860 | +54.0% |
| Other Long Term Investments | 2,137 | 2,180 | -2.0% |
| Intangible Assets Net Excluding Goodwill | 51,324 | — | — |
| Current Liabilities | |||
| Debt Current | 4,303 | 9,699 | -55.6% |
| Accounts Payable | 5,024 | 5,314 | -5.5% |
| Taxes Payable Current | 3,799 | 2,877 | +32.0% |
| Employee Related Liabilities Current | 3,036 | 3,383 | -10.3% |
| Deferred Revenue (Current) | 924 | 2,020 | -54.3% |
Show Product Lines breakouts |
|||
| Paxlovid and Comirnaty [Member] · Government and Government Sponsored [Member] | 790 | 2 | +39400.0% |
| Other Liabilities Current | 19,509 | 19,917 | -2.0% |
Show Product Lines breakouts |
|||
| Comirnaty [Member] · BioNTech [Member] | 426 | 375 | +13.6% |
| Total Current Liabilities | 36,596 | 43,211 | -15.3% |
| Current Portion of Long-Term Debt | 4,247 | 3,746 | +13.4% |
| Non-Current Liabilities | |||
| Long-Term Debt | 57,409 | 58,002 | -1.0% |
Show Long-Term Debt Type breakouts |
|||
| Unsecured Debt | 57,409 | 58,002 | -1.0% |
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 2,157 | 2,073 | +4.1% |
| Deferred Tax Liabilities | 2,467 | 2,158 | +14.3% |
| Liability For Uncertain Tax Positions Noncurrent | 3,401 | 5,905 | -42.4% |
| Other Non-Current Liabilities | 13,605 | 15,569 | -12.6% |
| Total Liabilities | 115,635 | 126,918 | -8.9% |
| Long-Term Debt (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign currency long-term debt [Member] | 874 | 836 | +4.5% |
| Contract With Customer Liability Noncurrent (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Paxlovid and Comirnaty [Member] · Government and Government Sponsored [Member] | 1 | 1.5 | -33.3% |
| Other Liabilities | |||
| Minority Interest | 295 | 272 | +8.5% |
| Stockholders' Equity | |||
| Common Stock | 481 | 480 | +0.2% |
| Additional Paid-In Capital | 94,248 | 93,477 | +0.8% |
| Treasury Stock Common Value | -115,011 | -114,760 | -0.2% |
| Retained Earnings | 121,150 | 121,059 | +0.1% |
| Accumulated Other Comprehensive Income | -8,066 | -7,971 | -1.2% |
| Total Stockholders' Equity | 92,801 | 92,286 | +0.6% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 93,096 | 92,558 | +0.6% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Net Prior Service Cost Credit | 99 | 61 | +62.3% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -442 | -447 | +1.1% |
| Accumulated Net Unrealized Investment Gain Loss | -19 | 46 | -141.3% |
| Accumulated Other Comprehensive Income | -8,066 | -7,971 | -1.2% |
| Accumulated Translation Adjustment | -7,705 | -7,631 | -1.0% |
| Additional Paid In Capital | 94,248 | 93,477 | +0.8% |
| Common Stock | 481 | 480 | +0.2% |
| Noncontrolling Interest | 295 | 272 | +8.5% |
| Parent | 92,801 | 92,286 | +0.6% |
| Retained Earnings | 121,150 | 121,059 | +0.1% |
| Treasury Stock Common | -115,011 | -114,760 | -0.2% |
| Total Liabilities & Equity | 208,731 | 219,476 | -4.9% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 4,905 | 5,222 | -6.1% |
Show Business Segments breakouts |
|||
| Biopharma [Member] · Operating Segments | 1,029 | 1,018 | +1.1% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 225 | 262 | -14.1% |
| Material Reconciling Items · Acquisition-Related Items [Member] | -4 | 4 | -200.0% |
| Material Reconciling Items · Amortization of Intangible Assets [Member] | 3,644 | 3,927 | -7.2% |
| Material Reconciling Items · Certain Significant Items [Member] | 11 | 11 | 0.0% |
| Asset Write Offs And Asset Impairment Charges | 864 | 1,080 | -20.0% |
| Deferred Income Taxes | -1,700 | -1,706 | +0.4% |
| Stock-Based Compensation | 574 | 700 | -18.0% |
| Pension And Other Postretirement Benefit Contributions Net Of Pension And Other Postretirement Benefit Expense | -418 | -466 | +10.3% |
| Other Non-Cash Items | -353 | -455 | +22.4% |
| Increase Decrease In Operating Capital | -6,944 | -5,992 | -15.9% |
| Net Cash from Operations | 6,356 | 6,023 | +5.5% |
| Investing Activities | |||
| Capital Expenditures | -1,784 | -1,992 | +10.4% |
| Payments To Acquire Short Term Investments | -10,308 | -3,957 | -160.5% |
| Proceeds From Sale Maturity And Collection Of Shortterm Investments | 13,236 | 2,630 | +403.3% |
| Payments For Proceeds From Short Term Investments With Original Maturities Of Three Months Or Less | -3,251 | 2,649 | -222.7% |
| Payments To Acquire Marketable Securities | -215 | -75 | -186.7% |
| Proceeds From Sale Maturity And Collection Of Longterm Investments | 504 | 1,541 | -67.3% |
| Proceeds From Sale Of Equity Method Investments | 6,311 | 3,491 | +80.8% |
| Other Investing Activities | 302 | -13 | +2423.1% |
| Net Cash from Investing | 4,795 | 4,275 | +12.2% |
| Financing Activities | |||
| Repayments Of Short Term Debt | -2,199 | -7,774 | +71.7% |
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | -897 | -2,590 | +65.4% |
| Proceeds From Issuance Of Long Term Debt | 3,687 | — | — |
| Repayments Of Long Term Debt | -3,750 | -2,250 | -66.7% |
| Payments Of Ordinary Dividends | -7,326 | -7,132 | -2.7% |
| Proceeds From Payments For Other Financing Activities | -415 | -455 | +8.8% |
| Net Cash from Financing | -10,900 | -12,026 | +9.4% |
| Supplemental | |||
| Income Taxes Paid | 3,671 | 3,172 | +15.7% |
| Interest Paid | 1,758 | 1,833 | -4.1% |
| Interest Paid Received Interest Rate Hedges | 95 | 31 | +206.5% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 36 | -37 | +197.3% |
| Net Change in Cash | 287 | -1,765 | +116.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,394 | 1,152 | +21.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.